Funds and ETFs Haleon plc

Equities

HLN

GB00BMX86B70

Pharmaceuticals

Real-time Estimate Cboe Europe 03:36:17 2024-06-10 am EDT 5-day change 1st Jan Change
327.5 GBX -0.85% Intraday chart for Haleon plc +0.18% +1.66%

ETFs positioned on Haleon plc

Name Weight AuM 1st Jan change Investor Rating
1.35% 142 M€ +11.55% -
0.99% 11 M€ +0.83% -
0.94% 4 M€ +15.27%
0.21% 51 M€ +9.03%
0.17% 6 M€ -.--%
0.12% 10 M€ -3.35% -
0.11% 2 M€ +9.19% -
0.11% 2 M€ -.--% -
0.09% 35 M€ +5.55% -
0.09% 7 M€ +5.53% -
0.08% 749 M€ +8.29%
0.04% 205 M€ -.--%
0.04% 1,166 M€ +0.26% -
0.04% 607 M€ +0.05% -
0.03% 0 M€ 0.00% -
0.03% 414 M€ +10.08% -
0.02% 36 M€ +9.83% -
0.02% 324 M€ +6.65% -
0.02% 40 M€ +6.57% -
0.01% 104 M€ +4.33% -
0.01% 32 M€ +4.30% -
0.01% 248 M€ +11.05% -
0.01% 55 M€ +1.07% -
0.00% 7 M€ +0.11% -
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (27.7%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - Pain relief medicines (23.5%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - medicines for digestive health (18.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - respiratory medicines (15.4%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; - vitamins, minerals and food supplements (14.5%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (40.2%), North America (37.1%), and Asia/Pacific (22.7%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
3.303 GBP
Average target price
3.646 GBP
Spread / Average Target
+10.40%
Consensus
  1. Stock Market
  2. Equities
  3. HLN Stock
  4. Funds and ETFs Haleon plc